Blood pressure independent effects of antihypertensive agents;Blutdruckunabhängige wirkungen von antihypertensiva

Internist

Volumn 46, Issue 5, 2005, Pages 548-556

  Wenzel, U ^a   Wolf, G ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Calcium antagonists; Diabetes mellitus; End organ damage; Hypertension; Renin antiotensin system

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CELL PROTECTION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG INHIBITION; ESSENTIAL HYPERTENSION; HUMAN; METABOLIC ACTIVATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS; HUMANS; HYPERTENSION; INFLAMMATION; KIDNEY DISEASES;

EID: 20044385793     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-005-1385-x     Document Type: Article

References (33)

1. Black HR, Elliott WJ, Grandits G et al. (2003) Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular End points (CONVINCE) trial. JAMA 289: 2073-2082
2. Braunwald E, Domanski MJ, Fowler SE et al. (2004) Angiotensin-converting- enzyme inhibition in stable coronary artery disease. N Engl J Med 351: 2058-2068
3. Brown MJ, Palmer CR, Castaigne A et al. (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356: 366-367
4. Burnier M, Rutschmann B, Nussberger J et al. (1993) Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22: 339-347
5. Carlberg B, Samuelsson O, Lindholm LH (2004) Atenolol in hypertension: is it a wise choice? Lancet 364: 1684-1689
6. Dahlof B, Devereux RB, Kjeldsen SE et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003
7. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO (1991) Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 338: 1281-1285
8. Fox KM (2003) EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782-788
9. Hansson L, Hedner T, Lund-Johansen P et al. (2000) Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the NORdic DILtiazem (NORDIL) study. Lancet 356: 359-365
10. Hansson L, Lindholm LH, Ekbom T et al. (1999) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with hypertension-2 study. Lancet 354: 1751-1756
11. Hansson L, Lindholm LH, Niskanen L et al. (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the CAptopril Prevention Project (CAPPP) randomised trial. Lancet 353: 611-616
12. Julius S, Kjeldsen SE, Weber M et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022-2231
13. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O (2003) Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatment and Lipid Profile In a North of Sweden Efficacy evaluation (ALPINE study). J Hypertens 21: 1563-1574
14. Lithell H, Hansson L, Skoog I et al. (2004) The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875-886
15. Mazak I, Fiebeler A, Muller DN et al. (2004) Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109: 2792-2800
16. Pfeffer MA, Swedberg K, Granger CB et al. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 362: 759-766
17. Pitt B, Remme W, Zannad F et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321
18. Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717
19. Ruggenenti P, Fassi A, Ilieva AP et al. (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941-1951
20. Schillinger W, Hermann HP, Hasenfuß G (2004) Differenzialtherapie der Herzinsuffizienz. Internist 45: 1378-1387
21. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057
22. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC (2002) Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40: 609-611
23. SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older subjects with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265: 3255-3264
24. Snow V, Barry P, Fihn SD et al., Chronic Stable Angina Panel (2004) Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 141: 562-567
25. Svensson P, de Faire U, Sleight P, Yusuf S, Östergren J (2001) Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE Substudy. Hypertension 38: 28-32
26. Taddei S, Virdis A, Ghiadoni L, Versari D, Salvetti G, Magagna A, Salvetti A (2003) Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 41: 950-955
27. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997
28. The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145-153
29. Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419
30. Weber MA, Julius S, Kjeldsen SE et al. (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363: 2049-2051
31. Wenzel UO, Dominiak P, Neumayer HH, Wolf G (2003) Hemmung des Fortschreitens von chronischen Nierenerkrankungen durch Blockierung des Renin-Angiotensin-Systems. Dtsch Ärztebl 100: A2072-2079
32. Wing LM, Reid CM, Ryan P et al. (2003) A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583-592
33. Wolf G, Butzmann U, Wenzel UO (2003) The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 93: 3-13